Impact of new medications on the treatment of immune TTP
Scully, Marie Howells, Lara Lester, William A
Scully, Marie
Howells, Lara
Lester, William A
Affiliation
University College Hospitals London NHS Foundation Trust; University Hospitals Birmingham NHS Foundation Trust
Other Contributors
Publication date
2025-02-06
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
The last decade has seen the introduction of 2 new licensed therapies for thrombotic thrombocytopenic purpura (TTP), caplacizumab and recombinant ADAMTS13 (rADAMTS13), for immune and congenital TTP (cTTP), respectively. They improve acute TTP outcomes, and reduce the need for plasma therapy, time to clinical response, and treatment burden. Future pathways need to replace plasma exchange in acute TTP and optimize/personalize rADAMTS13 in cTTP. Future emphasis should focus on additional monoclonals/treatments to tackle ADAMTS13 antibodies.
Citation
Scully M, Howells L, Lester WA. Impact of new medications on the treatment of immune TTP. Blood. 2025 Mar 27;145(13):1353-1357. doi: 10.1182/blood.2024026390.
Type
Article